KURA•benzinga•
Reported Sunday, FDA Grants Priority Review To Kura And Kyowa Kirin's Ziftomenib NDA, Targeting First Menin Inhibitor Approval In NPM1-Mutant AML By November 30
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 2, 2025 by benzinga